Perspectives on adherence and persistence with oral medications for cancer treatment
John Hohneker, Shilpa Shah-Mehta, Patricia S Brandt, John Hohneker, Shilpa Shah-Mehta, Patricia S Brandt
Abstract
Ensuring persistence, continuing treatment for the prescribed duration, and adherence-taking medication as prescribed-have been challenges for management of patients with oral cancer and for health care cost containment in real-world settings.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/3014515/bin/jop0011126880001.jpg)
The patients who persisted with letrozole either continued therapy (54%) or had a therapy gap but reinitiated treatment by the end of the year (23%; data on file, Novartis, East Hanover, NJ).
Source: PubMed